Ovid published a press release reporting fourth-quarter and full-year 2025 financial results and pipeline updates. Cash, cash equivalents and marketable securities totaled USD 90.4 million as of Dec. 31, 2025, and the company said this is expected to fund operations into late 2028, with warrant exercises potentially extending runway into 2029. Q4 revenue from royalty agreements rose more than doubled to USD 0.7 million, while FY revenue increased more than doubled to USD 7.3 million, driven by royalties on net sales and recognition of a one-time USD 7 million payment primarily related to future royalties. Q4 R&D expense increased 11.86% to USD 6.6 million and Q4 G&A expense rose 30.61% to USD 6.4 million, with the R&D increase tied to higher clinical activity and the G&A increase linked to non-routine investment advisory fees. Q4 net income was USD 9.7 million, reflecting a gain of about USD 21 million from an adjustment in fair value of a long-term equity investment, while FY net loss was USD 17.4 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603180605PRIMZONEFULLFEED9674275) on March 18, 2026, and is solely responsible for the information contained therein.
Comments